{
  "pmcid": "11482247",
  "sha256": "669a264f47b20af1d4a564fdb4ddd7684372cf4d5a1857f4006b8ce9445582c7",
  "timestamp_utc": "2025-11-09T23:16:42.513303+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 12.893852459016394,
    "reading_ease": 20.728128415300574,
    "word_count": 244
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Super-oxidized Solution for Surgical-site Infection Prevention in Open Appendicectomy"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "multicentre, triple-blind, randomised controlled trial"
      },
      "Participants": {
        "score": 2,
        "evidence": "Patients aged 13 years and older with perforated appendicitis undergoing open appendicectomy"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomised to receive peritoneal and wound lavage with either super-oxidized solution or normal saline"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to evaluate the effect of super-oxidized solution in reducing SSI risk."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was SSI within 30 days post-surgery."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated with allocation concealment using opaque, sequentially numbered, sealed envelopes."
      },
      "Blinding": {
        "score": 3,
        "evidence": "Patients, surgeons, outcome assessors, and statisticians were blinded."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "A total of 102 patients were randomised (51 per group)"
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "included in the intention-to-treat analysis"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The super-oxidized solution group showed a significant reduction in overall SSI (15.6% vs. 37.2%; RR 0.42; 95% CI 0.20 to 0.87; P = 0.014)"
      },
      "Harms": {
        "score": 1,
        "evidence": "No adverse events were reported."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "ClinicalTrial.gov Identifier: NCT04512196"
      },
      "Funding": {
        "score": 1,
        "evidence": "Funding: Ministry of Health Research Grant"
      }
    },
    "total_score": 25,
    "max_score": 25
  }
}